A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Financial Summary
| Share Statistics | GALDY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $46,776.8 | $671.5 | 93% |
|
| Shares Out (Mil) | 234.8 | 43.5 | 79% |
|
| Institutional Ownership | 50.0% | 84.6% | 30% |
|
| Float (Mil) | 131.3 | 47.3 | 66% |
|
| Beta | -0.10 | 0.71 | 4% |
|
| Avg Daily Volume (000s) | 82 | 293 | 34% |
|
| Price Change (52-week) |
16.9% | 69.4% | 61% |
|
| Growth | GALDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | 68% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GALDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5,923 | $317 | 77% |
|
| Net Income (TTM) (Mil) | $863 | ($11) | 85% |
|
| EPS (TTM) | $3.686 | ($0.700) | 81% |
|
| Operating Cash Flow (TTM) (Mil) | $1,206 | ($6) | 83% |
|
| Net Cash Flow (TTM) (Mil) | $380 | $5 | 89% |
|
| Long-Term Debt (Q1) (Mil) | $2,653 | $6 | 78% |
|
| Enterprise Value (Q1) (Mil) | $53,419 | $536 | 93% |
|
| Valuation | GALDY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.81 | na |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | GALDY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.4% | 68.1% | 80% |
|
| Net Margin | 14.6% | (1.4%) | 72% |
|
| ROA | 6.5% | (24.1%) | 77% |
|
| ROE | 10.8% | (21.0%) | 59% |
|
| Liabilities to Assets | 39.3% | 32.3% | 30% |
|
| F-Score | na | 3 | na |
|
Galderma Group AG did not pass any screens on 9/3/2026.
